Brimonidine 0.025% to reduce redness from netarsudil/latanoprost

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults 18–65 with open‑angle glaucoma or ocular hypertension who have at least grade 2 conjunctival hyperemia after using netarsudil 0.02%/latanoprost 0.005% will receive brimonidine tartrate ophthalmic 0.025% alongside their current regimen. The Phase 4 interventional protocol is conducted at a single Vision Source site and includes baseline and follow‑up visits to measure changes in hyperemia using the Efron scale, monitor visual acuity, and record safety/tolerability. A protocolized washout per FDA guidance for prior topical agents may be required before certain visits. The primary focus is on reduction in ocular redness and treatment tolerability while maintaining intraocular pressure control.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* 1\. Adult patients 18-65 years old diagnosed with open-angle glaucoma or ocular hypertension.

  2\. Currently on netarsudil 0.02%/latanoprost 0.005% monotherapy for a minimum of 2-6 weeks.

  3\. Able to move from current topical glaucoma treatment to netarsudil 0.02%/latanoprost 0.005% for a minimum of 4 weeks or longer based on FDA recommended washout per drug classification prior to Visit 3.

  4\. Experience conjunctival redness as graded on the Efron scale of at least grade 2 after minimum of 4 weeks on netarsudil 0.02%/latanoprost 0.005% mono-therapy or longer based on recommended washout per drug classification 4. Have a best corrected Visual Acuity by Snellen chart of 20/30 or better in study eye.

  5\. Are willing and able to self-administer or have an able person available to assist with administration of study drug.

Willing and able to comply with study procedures and attend follow-up visits.

Exclusion Criteria:

1. Allergy or hypersensitivity to brimonidine or other components of brimonidine tartrate 0.025% or netarsudil 0.02%/latanoprost 0.005%.
2. Use of any other topical ocular medications.
3. Active ocular infection, inflammation unrelated to glaucoma therapy, uveitis, iritis or congenital aphakia.
4. Have pterygium/pinguecula, chemosis, episcleritis, scleritis (or any condition that may affect hyperemia grading) in the opinion of the investigator
5. Have moderate or severe dry eyes.
6. Pregnant, plan to become pregnant or breastfeeding.
7. Concurrent or past use in the last 90 days of vasoconstrictive ocular drops other than brimondine 0.025%
8. Have undergone previous incision IOP lowering surgeries.
9. Have undergone previous laser surgery for glaucoma (selective laser trabeculoplasty (SLT) or argon laser trabeculoplasty (ALT)), or microinvasive glaucoma surgery (MIGS) with 6 months of screening.
10. Have had intraocular or per-ocular surgery within the past 3 months.
11. Advanced glaucoma or c/d ratio greater than 0.8. Are non-responsive to topical treatment with netarsudil 0.02%/latanoprost 0.005%.
12. In the judgement of the investigator, have previous or currently active clinically significant systemic or ocular disease in either eye that could affect study outcomes.

Where it's running

• Vision Source
  Kansas City, Missouri, United States Recruiting

Study contacts

• Study coordinator: Crystal Remington Optometrist, OD
• Email: drremington@vseyecare.com
• Phone: 816-531-9100

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Balance training for people with glaucoma

  A randomized study tests whether a structured eight-week balance program helps adults with glaucoma improve balance, reduce fall risk, and lessen fear of falling.

  Recruiting Kanuni Sultan Suleyman Training and Research Hospital · Küçükçekmece, Istanbul · NCT07910955

• Eye drops Rhopressa vs Timolol to protect nerve cells in glaucoma

  In adults with open-angle glaucoma, this study tests whether Rhopressa helps preserve retinal nerve cells better than Timolol while both lower eye pressure.

  Recruiting Phase 4 Indiana University · Bloomington, Indiana · NCT07847073

• Comparison of FT-1000 non-contact tonometry with Goldmann applanation tonometry in glaucoma patients

  This study tests whether the FT-1000 non-contact tonometer gives measurements that agree with the Goldmann applanation tonometer in adults with glaucoma.

  Recruiting Tomey Corporation · Jacksonville, Florida · NCT07804277

• Removing the ripcord from a glaucoma drainage device after 3 months

  This study tests whether removing the ripcord from an implanted glaucoma drainage device changes eye pressure for adults with open-angle glaucoma.

  Recruiting Duke University · Durham, North Carolina · NCT07803536

• Glaucoma and Brain Changes: How Brain Structure and Size See What Glaucoma Is Doing

  This study tests whether glaucoma is linked to broader brain changes by comparing brain MRI and eye health over time in people with glaucoma and matched controls.

  Recruiting University Hospital, Bordeaux · Bordeaux · NCT07802769

• Long-Term Results After Ab-interno Trabeculotomy for Glaucoma

  This study tests whether ab-interno trabeculotomy with the Trabectome can provide sustained intraocular pressure reduction in glaucoma patients who had the procedure between 2019 and 2021.

  Recruiting Wuerzburg University Hospital · Würzburg, Bavaria · NCT07780916

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.